Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland.
PLoS One. 2007 Apr 18;2(4):e378. doi: 10.1371/journal.pone.0000378.
APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) has antiretroviral activity associated with the hypermutation of viral DNA through cytosine deamination. APOBEC3G has two cytosine deaminase (CDA) domains; the catalytically inactive amino-terminal domain of APOBEC3G (N-CDA) carries the Vif interaction domain. There is no 3-D structure of APOBEC3G solved by X-ray or nuclear magnetic resonance.
METHODOLOGY/PRINCIPAL FINDINGS: We predicted the structure of human APOBEC3G based on the crystal structure of APOBEC2. To assess the model structure, we evaluated 48 mutants of APOBEC3G N-CDA that identify novel variants altering DeltaVif HIV-1 infectivity and packaging of APOBEC3G. Results indicated that the key residue D128 is exposed at the surface of the model, with a negative local electrostatic potential. Mutation D128K changes the sign of that local potential. In addition, two novel functionally relevant residues that result in defective APOBEC3G encapsidation, R122 and W127, cluster at the surface.
CONCLUSIONS/SIGNIFICANCE: The structure model identifies a cluster of residues important for packaging of APOBEC3G into virions, and may serve to guide functional analysis of APOBEC3G.
APOBEC3G(载脂蛋白 B mRNA 编辑酶,催化多肽样 3G)具有抗逆转录病毒活性,通过胞嘧啶脱氨酶使病毒 DNA 发生高突变。APOBEC3G 有两个胞嘧啶脱氨酶(CDA)结构域;APOBEC3G 的无催化活性氨基端结构域(N-CDA)携带 Vif 相互作用结构域。目前还没有通过 X 射线或核磁共振解决的 APOBEC3G 的 3-D 结构。
方法/主要发现:我们基于 APOBEC2 的晶体结构预测了人 APOBEC3G 的结构。为了评估模型结构,我们评估了 48 种 APOBEC3G N-CDA 的突变体,这些突变体确定了改变ΔVif HIV-1 感染性和 APOBEC3G 包装的新型变体。结果表明,关键残基 D128 暴露在模型表面,具有负的局部静电势。D128K 突变改变了局部电势的符号。此外,导致 APOBEC3G 包封缺陷的两个新的功能相关残基 R122 和 W127 在表面聚集。
结论/意义:结构模型确定了一组对 APOBEC3G 包装到病毒颗粒中很重要的残基,可能有助于指导 APOBEC3G 的功能分析。